Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July